This previously undescribed HAPLN1-PTR1 receptor complex on the MM cells may provide a potential therapeutic target to modulate the pro-tumorigenic effect of HAPLN1 without altering its vital role in cartilage biogenesis and maintenance of ECM structure. Here, HAPLN1 is linked to Miyoshi myopathy.